Asia-Pacific Non Hodgkin Lymphoma Therapeutics Industry Research Report and Forecast to 2020

1
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific
Markets to 2020 Novel Technologies Show
Considerable Promise in Relapsed/Refractory
Setting- By GBI Research
Published Sept 2014 No of Pages 96 Single
User PDF US 4995 Corporate User PDF US 14985

• View Complete Report _at_ http//www.lifescienceindus
  tryresearch.com/non-hodgkin-lymphoma-therapeutics-
  in-asia-pacific-markets-to-2020-novel-technologies
  -show-considerable-promise-in-relapsedrefractory-s
  etting.html .

2
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific
Markets to 2020 Novel Technologies Show
Considerable Promise in Relapsed/Refractory
Setting
Summary The leading business intelligence
provider, has released its latest research,
Non-Hodgkin Lymphoma Therapeutics in
Asia-Pacific Markets to 2020 Novel Technologies
Show Considerable Promise in Relapsed/Refractory
Setting, which provides in-depth insights into
the indication. It gives an estimation of market
size for 2013 along with forecasts until 2020 for
the Asia-Pacific (APAC) region, which comprises
Australia, China, India and Japan. It also covers
disease epidemiology, treatment algorithms,
treatment patterns, in-depth analysis of clinical
trials including failure rates and pipeline
analysis, and analysis of deals relevant to
Non-Hodgkin Lymphoma (NHL). The market in the
APAC region was worth an estimated 1.1 billion
in 2013 and is expected to grow at a Compound
Annual Growth Rate (CAGR) of 6.6 to 1.7 billion
in 2020. The expected launches of promising
drugs, including novel protein kinase inhibitors
and next-generation monoclonal antibodies, as
well as the continued use of the current
blockbuster, Rituxan/Mabthera, will be the key
growth drivers. The launch of premium-priced
novel glycol-engineered antibody obinutuzumab
kinase inhibitors including idelalisib and
ibrutinib and the mTOR inhibitor everolimus are
also expected to have a significant impact, as is
the anticipated approval of immunomodulatory
agent Revlimid as a maintenance setting. An
increasingly aging population and a year-on-year
increase in the number of incident cases will
provide an additional boost. However, the recent
implementation of a price ceiling on essential
drugs in India anticipated pricing restrictions
in China and low access, penetration and price
erosion due to generic dominance, especially in
India, stand to curtail the APAC NHL market.
Buy a Copy of this Report _at_ http//www.lifescience
industryresearch.com/purchase?rname22897 .
3
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific
Markets to 2020 Novel Technologies Show
Considerable Promise in Relapsed/Refractory
Setting

• Scope
• The report analyzes treatment usage patterns,
  market characterization, the pipeline, and key
  licensing and co-development deals in the four
  APAC markets of Australia, China, India and
  Japan. It includes
• A brief introduction to NHL, including the
  diseases pathogenesis, etiology, diagnosis and
  treatment algorithms
• In-depth analysis of currently marketed drugs for
  NHL, examining their safety, efficacy, treatment
  patterns and strengths/weaknesses and including a
  heat map that compares the drugs in terms of
  safety and efficacy
• A comprehensive review of the pipeline for NHL,
  including individual analysis of a number of
  late-stage pipeline drugs that are likely to
  enter the market during the forecast period the
  pipeline is analyzed on the basis of Phase
  distribution, molecule type, program type,
  mechanism of action and molecular target
• Additional in-depth analysis of pipeline drug
  clinical trials by Phase, trial size, trial
  duration and program failure rate for each
  molecule type
• Multi-scenario forecast data of the market to
  2020, taking into account how the market may be
  affected by the introduction of new drugs, the
  expiry of key patents on current drugs and the
  changes in disease epidemiology across the key
  developed markets
• Discussion of the drivers of and barriers to
  market growth
• In-depth analysis of all licensing and
  co-development deals that have occurred in the
  NHL market since 2006
• Single User License US 4995
• Inquire for a discount on this report _at_
  http//www.lifescienceindustryresearch.com/discoun
  t?rname22897 .

4
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific
Markets to 2020 Novel Technologies Show
Considerable Promise in Relapsed/Refractory
Setting

• Reasons to buy
• The report will enhance your decision-making
  capability by allowing you to -
• Understand the NHL pipeline and the factors that
  indicate that it is becoming more innovative
• Examine detailed profiles of promising pipeline
  products and gain an insight into how they are
  likely to compete in the market and who their
  main competitors will be
• Follow the trends in NHL clinical trial size and
  duration in relation to industry averages and
  assess the potential risk of future developmental
  programs according to mechanism of action by
  considering the recorded clinical trial failure
  rates
• Observe the potential growth patterns expected
  for the NHL market over the forecast period,
  identify which countries are expected to make the
  biggest contribution to this growth, and devise a
  more effective country strategy through an
  understanding of key drivers and barriers in the
  NHL market
• Accelerate and strengthen your market position by
  identifying key companies for strategic
  partnerships

Inquire Before Buying This Report _at_
http//www.lifescienceindustryresearch.com/inquire
-before-buying?rname22897 .
5
About us Life Science Industry
Research brings to you to the latest reports in
market research on Biotechnology, Diagnostics,
Healthcare, Medical Devices and Pharmaceuticals
segments from leading research publishers across
the globe. These reports also cover data and
information on sub-segments and sectors under
these life sciences categories.Contact us
(sales_at_lifescienceindustryresearch.com / 1 888
391 5441) for any of your research requirements
or topics of interest. Our sales research
associates will be happy to help you find
relevant market data.Website
www.lifescienceindustryresearch.com
Browse Latest Industry News, Updates, Trends,
Opportunities, Scenario all over the world _at_